

Special Issue

Measurable Residual Disease in Cancer

Message from the Guest Editors

Measurable residual disease (MRD) refers to the presence of cancer cells below the threshold of detection when using conventional methods of assessing response to treatment. In this Special Issue, a panel of internationally recognized experts will focus on the current and future role of MRD in cancer with respect to MRD assessment techniques, MRD as a prognostic/predictive factor or therapeutic target as well as MRD-based directions in the anticancer drugs development. Potential topics include, but are not limited to:

- Systematic reviews on the current role of MRD in particular types of cancer
- Novel methods of MRD assessment and MRD standardization efforts in cancer
- Design and results of clinical trials testing MRD-driven treatment strategies
- Original studies reporting treatment of disease at MRD or subclonal levels in clinical practice
- Significance of genomic and spatial heterogeneity of MRD
- Role of tumor microenvironment regarding MRD persistence/eradication
- MRD as surrogate endpoint for new anti-cancer drug development and approval

Guest Editors

Prof. Dr. Krzysztof Jamrozia

Department of Hematology, Transplantation and Internal Medicine,
Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland

Dr. Bartosz Pula

Department of Hematology, Institute of Hematology and Transfusion
Medicine, 02-776 Warsaw, Poland

Deadline for manuscript submissions

closed (30 November 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/130366

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)